XYLONOR Spray Solution 15% w/w

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

lidocaine, Quantity: 150 mg/g; cetrimide, Quantity: 1.5 mg/g

Commercializzato da:

Specialites Septodont Pty Ltd

INN (Nome Internazionale):

Cetrimide,lidocaine (lignocaine)

Forma farmaceutica:

Spray, solution

Composizione:

Excipient Ingredients: saccharin; Spearmint oil; dipropylene glycol; ethanol

Via di somministrazione:

Topical, Buccal

Confezione:

1 x 36G

Tipo di ricetta:

(S4) Prescription Only Medicine

Indicazioni terapeutiche:

INDICATIONS AS AT 1 JANUARY 1991: Topical anaesthesia of the mucous membrane of the buccal cavity, before: Nerve block or local anaesthetic injection, Extraction of mobile, deciduous or permanent teeth, Adjustment and fitting of crowns and bridges, Or adjustmentof bands in orthodontic treatments; Lancing of sub mucosal abscesses, Scaling.

Dettagli prodotto:

Visual Identification: Clear solution.; Container Type: Bottle; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Registered

Data dell'autorizzazione:

1994-07-13

Scheda tecnica

1
AUSTRALIAN PRODUCT INFORMATION – XYLONOR (LIDOCAINE
(LIGNOCAINE), CETRIMIDE) TOPICAL ANAESTHETIC
1
NAME OF THE MEDICINE
Lidocaine (lignocaine), cetrimide
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
XYLONOR SPRAY
Lidocaine (lignocaine) base
............................................... 15 g
Cetrimide
................................................................................
0.15 g
Excipient q.s. ad.
.................................................................. 100
g
Contains Saccharin and Alcohol (ethanol)
XYLONOR GEL
Lidocaine (lignocaine) base
................................................. 5 g
Cetrimide
................................................................................
0.15 g
Excipient q.s. ad.
................................................................. 100
mL
Contains Saccharin
XYLONOR PELLETS
Lidocaine (lignocaine) base
................................................. 5 g
Cetrimide
................................................................................
0.15 g
Excipient q.s. ad.
................................................................. 100
mL
Contains Saccharin
One impregnated pellet contains approximately 100 mg of the above
solution.
For the full list of excipients, see Section 6.1 List of excipients.
XYLONOR is an association of:
•
a powerful anaesthetic, Lidocaine (lignocaine),
a bactericide, Cetrimide, in a non-irritant, water-soluble excipient.
3
PHARMACEUTICAL FORM
XYLONOR GEL: clear gel
XYLONOR PELLETS: dressing, medicated; pellet soaked in solution
XYLONOR SPRAY: Spray with clear solution
2
4
CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
XYLONOR GEL
Topical anaesthesia and disinfection of the mucosa before:
-
injections
-
extraction of mobile, deciduous or permanent teeth
-
extraction of teeth due to pyorrhoea
-
adjusting and fitting of crowns & bridges
-
lancing of abscesses
-
scaling
Prevention of gagging during impression taking.
XYLONOR PELLETS
Topical anaesthesia and disinfection of the mucosa before:
-
injections
-
extraction of mobil